Current Development, Obstacle and Futural Direction of Induced Pluripotent Stem Cell and Mesenchymal Stem Cell Treatment in Degenerative Retinal Disease

Chiang, Ming-Cheng; Chern, Edward

doi:10.3390/ijms23052529

Cited by 6 publications

(1 citation statement)

References 166 publications

(178 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advances in understanding the retina’s neuroimmune interactions and oxidative stress tolerance provide alternative avenues for maintaining retinal health ( Wang et al, 2020 ; Wu et al, 2021 ), especially in the context of microglial maintenance and antioxidant cocktails ( Yu et al, 2004 ; Shen et al, 2005 ; Komeima et al, 2006 ; Komeima et al, 2007 ; Punzo et al, 2012 ; O’Koren et al, 2019 ). Given that the vast number of disease-causing mutations are in genes selectively or primarily expressed by photoreceptors ( Rosenfeld et al, 1992 ; McLaughlin et al, 1993 ), photoreceptor transplantation has garnered enthusiasm as a therapeutic solution ( Comyn et al, 2010 ; Garita-Hernandez et al, 2021 ; Chiang and Chern, 2022 ), especially in combination with induced pluripotent stem cells (iPSCs) ( Zhong et al, 2014 ; Takagi et al, 2019 ; Watari et al, 2023 ), embryonic stem cells (ESCs) ( Da Cruz et al, 2018 ), mesenchymal stem cells ( Bartsch et al, 2008 ; Gasparini et al, 2019 ; Mahato et al, 2020 ; Sharma and Jaganathan, 2021 ; Zerti et al, 2021 ) (MSCs), chemically-induced photoreceptor-like cells (CiPCs) ( Mahato et al, 2020 ) or neural stem cells ( Liu et al, 2003 ; Coles et al, 2004 ; Frøen et al, 2013 ). Transplanting retinal pigmented epithelial (RPE) cells also warrants consideration, given the critical role of the RPE in providing the photoreceptors with the necessary support for maintaining the visual cycle and recycling metabolites.…”

Section: Introductionmentioning

confidence: 99%

Gene-agnostic approaches to treating inherited retinal degenerations

Chew

Iannaccone²

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Most patients with inherited retinal degenerations (IRDs) have been waiting for treatments that are “just around the corner” for decades, with only a handful of seminal breakthroughs happening in recent years. Highlighting the difficulties in the quest for curative therapeutics, Luxturna required 16 years of development before finally obtaining United States Food and Drug Administration (FDA) approval and its international equivalents. IRDs are both genetically and phenotypically heterogeneous. While this diversity offers many opportunities for gene-by-gene precision medicine-based approaches, it also poses a significant challenge. For this reason, alternative (or parallel) strategies to identify more comprehensive, across-the-board therapeutics for the genetically and phenotypically diverse IRD patient population are very appealing. Even when gene-specific approaches may be available and become approved for use, many patients may have reached a disease stage whereby these approaches may no longer be viable. Thus, alternate visual preservation or restoration therapeutic approaches are needed at these stages. In this review, we underscore several gene-agnostic approaches that are being developed as therapeutics for IRDs. From retinal supplementation to stem cell transplantation, optogenetic therapy and retinal prosthetics, these strategies would bypass at least in part the need for treating every individual gene or mutation or provide an invaluable complement to them. By considering the diverse patient population and treatment strategies suited for different stages and patterns of retinal degeneration, gene agnostic approaches are very well poised to impact favorably outcomes and prognosis for IRD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Gene-agnostic approaches to treating inherited retinal degenerations

Chew

Iannaccone²

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

Hydrogels in Gene Delivery Techniques for Regenerative Medicine and Tissue Engineering

Xu,

Zhang,

Zhu

et al. 2024

Macromolecular Bioscience

View full text Add to dashboard Cite

Hydrogels are three‐dimensional networks swollen with water. They are biocompatible, strong, moldable, and are emerging as a promising biomedical material for regenerative medicine and tissue engineering to deliver therapeutic gene. The excellent natural extracellular matrix simulation properties of hydrogels enable them to be co‐cultured with cells or enhance the expression of viral or non‐viral vectors. Its biocompatibility, high strength and degradation performance also make the action process of carriers in tissues more ideal, making it an ideal biomedical material. It has been shown that hydrogel‐based gene delivery technologies have the potential to play therapy‐relevant roles in organs such as bone, cartilage, nerve, skin, reproductive organs, and liver in animal experiments and preclinical trials. This paper reviews recent articles on hydrogels in gene delivery and explains the manufacture, applications, developmental timeline, limitations, and future directions of hydrogel‐based gene delivery techniques.This article is protected by copyright. All rights reserved

show abstract

Mesenchymal stem cells therapy for retinal diseases

Taher¹,

Abdelhamid²

2023

The Eye, Volume 4

View full text Add to dashboard Cite

Current Development, Obstacle and Futural Direction of Induced Pluripotent Stem Cell and Mesenchymal Stem Cell Treatment in Degenerative Retinal Disease

Cited by 6 publications

References 166 publications

Gene-agnostic approaches to treating inherited retinal degenerations

Gene-agnostic approaches to treating inherited retinal degenerations

Hydrogels in Gene Delivery Techniques for Regenerative Medicine and Tissue Engineering

Mesenchymal stem cells therapy for retinal diseases

Contact Info

Product

Resources

About